Vaccines · Nov 7, 2026
Shifts in Liver Cancer Attribution Composition, Lifetime Risk and Life Expectancy in the Western Pacific Region: A GBD 2023 Analysis
By Ding Y, Li P, Li X et al.
Background: Liver cancer is a leading cause of cancer mortality worldwide, with the Western Pacific Region (WPR) bearing a disproportionate share of the global burden. Although the HBV vaccine has served as primary prevention against liver cancer for many years, the current trends in attribution and the long-term patterns of lifetime risk and life expectancy impact remain poorly estimated. Methods: Using the Global Burden of Disease 2023 database, liver cancer incidence, mortality, and disability adjusted life years (DALYs) in the WPR from 2000 to 2023 were analysed, along with trends over time, focusing on trends in HBV-attributable burden in relation to vaccination coverage. The lifetime risk of liver cancer was estimated using the adjusted-for-multiple-primaries (AMP), which quantifies an individual’s lifetime probability of developing or dying from liver cancer. Cause-deleted life tables were used to estimate, under a counterfactual scenario and at the societal level, the gain in life expectancy at birth that would result from eliminating liver cancer deaths. Results: Age-standardised incidence and mortality rates of liver cancer declined in the WPR, but the absolute burden increased, accounting for 46.04% and 44.90% of the global totals in 2023, and YLLs accounted for 98.93% of DALYs. Moreover, men comprised 73.49% of cases and 72.50% of deaths (male-to-female ratios 2.6:1 and 2.77:1), and deaths at 75+ years reached 66,510, the greatest burden among older men. HBV fell from 53.52% to 49.38%, while HCV rose from 27.59% to 28.98% and alcohol from 8.44% to 10.50%, with HCV and alcohol attributable deaths increasing to 66,082.68 and 23,937.51, respectively. Meanwhile, lifetime incidence and mortality risks remained high (1.34% and 1.18%). Compared with countries where mortality risk declined, Mongolia had the highest lifetime mortality risk at 8.87%, up from 4.56% in 2000, with HCV and alcohol each contributing slightly more than HBV. Eliminating liver cancer yielded a gain of approximately 79 days, with the largest potential gain observed in Mongolia, at approximately 605 days. Conclusions: The attribution composition of liver cancer in the WPR is shifting from HBV towards HCV and alcohol. With HBV vaccination coverage increasing annually to over 90, the observed trends are consistent with the beneficial role of HBV vaccine control in liver cancer reduction, particularly in Mongolia. While consolidating vaccination, strategies should be adjusted to strengthen HCV antiviral treatment and alcohol and metabolic risk control. Risk-based surveillance and equitable care should also be promoted through tiered, differentiated strategies.